Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep-Dec;11(3):207-212.
doi: 10.4103/ojo.OJO_29_2017.

Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes

Saurabh Shrivastava  1 , Priyanka Patkar  1 , Reshma Ramakrishnan  1 , Minal Kanhere  1 , Zahna Riaz  1
Affiliations

Efficacy of rebamipide 2% ophthalmic solution in the treatment of dry eyes

Saurabh Shrivastava et al. Oman J Ophthalmol. 2018 Sep-Dec.

Abstract

Aim: The aim of this study is to evaluate the efficacy of 2% rebamipide ophthalmic solution on the tear functions and ocular surface status in patients with dry eyes.

Materials and methods: A prospective study was carried out on forty eyes of patients having signs and symptoms of dry eye. Two percent rebamipide ophthalmic solution was applied four times a day for a period of 4 weeks. Patients were evaluated on the basis of dry eye-related symptom score, tear film break-up time (TFBUT), tear meniscus height, fluorescein ocular surface staining score (FOSS), and the Schirmer's test at the end of 2, 4, 6, and 12 weeks and their values were compared with the baseline.

Results: Significant improvement was noted in the mean dry eye-related symptom score, TBUT, and the FOSS values from the baseline at the end of 2, 4, 8, and 12 weeks. The values of tear meniscus height and Schirmer's test were improved at the end of 8 weeks but were not statistically significant.

Conclusion: Nearly 2% rebamipide ophthalmic solution provided relief in the symptoms of patients having dry eyes. It also prevented further ocular surface damage and aided in stabilizing the tear film.

Keywords: Dry eye; mucin secretagogue; rebamipide.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Symptoms score, TFBUT, Schirmer's score, fluorescein ocular staining score and Rose Bengal score from baseline up to 12 weeks
Figure 2
Figure 2
Symptoms score
Figure 3
Figure 3
Schirmer's score value
Figure 4
Figure 4
Fluorescein ocular staining score values
See this image and copyright information in PMC

References

    1. Zeev MS, Miller DD, Latkany R. Diagnosis of dry eye disease and emerging technologies. Clin Ophthalmol. 2014;8:581–90. - PMC - PubMed
    1. Sharma B. Dry eye: Demography and attributable risk factors. Postgrad Med J NAMS. 2011;11:20–1.
    1. Lemp MA. Management of the dry-eye patient. Int Ophthalmol Clin. 1994;34:101–13. - PubMed
    1. Tsubota K. New approaches to dry-eye therapy. Int Ophthalmol Clin. 1994;34:115–28. - PubMed
    1. Baldone JA, Kaufman HE. Extended wear contact lenses. Ann Ophthalmol. 1983;15:595–6. - PubMed